Li C - Search Results

1

p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.

Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, Kong Y, Li C, Zhang Z, Liu J, Jones K, Napier D, Lee EY, Wang C, Liu X. Liu J, et al. Among authors: li c. Oncogene. 2020 May;39(19):3939-3951. doi: 10.1038/s41388-020-1270-z. Epub 2020 Mar 23. Oncogene. 2020. PMID: 32203167 Free PMC article.

2

NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.

Farah E, Li C, Cheng L, Kong Y, Lanman NA, Pascuzzi P, Lorenz GR, Zhang Y, Ahmad N, Li L, Ratliff T, Liu X. Farah E, et al. Among authors: li c, li l. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2. J Biol Chem. 2019. PMID: 30940724 Free PMC article.

3

Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.

Chen X, Liu J, Cheng L, Li C, Zhang Z, Bai Y, Wang R, Han T, Huang C, Kong Y, Feng F, Liu X. Chen X, et al. Among authors: li c. Prostate. 2020 Feb;80(3):256-266. doi: 10.1002/pros.23939. Epub 2019 Dec 19. Prostate. 2020. PMID: 31856338

4

Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.

Li C, Lanman NA, Kong Y, He D, Mao F, Farah E, Zhang Y, Liu J, Wang C, Wei Q, Liu X. Li C, et al. J Biol Chem. 2020 Apr 17;295(16):5470-5483. doi: 10.1074/jbc.RA119.011385. Epub 2020 Mar 17. J Biol Chem. 2020. PMID: 32184358 Free PMC article.

5

[No title available]

[No authors listed] [No authors listed] PMID: 33509588

6

Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.

Mao F, Kong Y, Liu J, Rao X, Li C, Donahue K, Zhang Y, Jones K, Zhang Q, Xu W, Liu X. Mao F, et al. Among authors: li c. Prostate. 2022 Jun;82(8):917-932. doi: 10.1002/pros.24336. Epub 2022 Mar 24. Prostate. 2022. PMID: 35322879 Free PMC article.

7

Epigenetics in prostate cancer treatment.

Jones K, Zhang Y, Kong Y, Farah E, Wang R, Li C, Wang X, Zhang Z, Wang J, Mao F, Liu X, Liu J. Jones K, et al. Among authors: li c. J Transl Genet Genom. 2021;5:341-356. doi: 10.20517/jtgg.2021.19. Epub 2021 Aug 27. J Transl Genet Genom. 2021. PMID: 35372800 Free PMC article.

8

GSTM2 is a key molecular determinant of resistance to SG-ARIs.

Li C, Liu J, He D, Mao F, Rao X, Zhao Y, Lanman NA, Kazemian M, Farah E, Liu J, Ngule CM, Zhang Z, Zhang Y, Kong Y, Li L, Wang C, Liu X. Li C, et al. Among authors: li l. Oncogene. 2022 Sep;41(40):4498-4511. doi: 10.1038/s41388-022-02444-1. Epub 2022 Aug 29. Oncogene. 2022. PMID: 36038661 Free PMC article.

9

The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET.

Kong Y, Allison DB, Zhang Q, He D, Li Y, Mao F, Li C, Li Z, Zhang Y, Wang J, Wang C, Brainson CF, Liu X. Kong Y, et al. Among authors: li c, li y, li z. Sci Signal. 2022 Oct 4;15(754):eabj4009. doi: 10.1126/scisignal.abj4009. Epub 2022 Oct 4. Sci Signal. 2022. PMID: 36194647 Free PMC article.

10

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer.

Liu J, Zhao Y, He D, Jones KM, Tang S, Allison DB, Zhang Y, Chen J, Zhang Q, Wang X, Li C, Wang C, Li L, Liu X. Liu J, et al. Among authors: li c, li l. Cell Rep Med. 2023 Apr 18;4(4):101015. doi: 10.1016/j.xcrm.2023.101015. Cell Rep Med. 2023. PMID: 37075701 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82,224 results

Search Page